Single-center retrospective study of thromboembolic complications in Grade II–IV gliomas


  • The risk of venous thromboembolism (VTE) is increased in patients with Grades II–III glioma compared with the general population, and the risk of VTE is decreased in the presence of an isocitrate dehydrogenase (IDH) mutation.

Why this matters

  • VTE is a known complication of glioblastoma (Grade IV), but the incidence of VTE in lower-grade gliomas (Grade II–III) is not well established.

  • Classification of gliomas has now incorporated genetic information (as per WHO guidelines) and there has been a growing interest in evaluating the association of genetic subtypes with clinical characteristics.